RoC

RoC is a French skincare brand founded in Paris in 1957 by the pharmacist Jean-Charles Lissarrague, who created it at the Rogé Cavaillès pharmacy. The name is a contraction of "Rogé Cavaillès." From the start the company focused on gentle, dermatologically tested formulas, and it built its later reputation on anti-ageing skincare and stabilised retinol.

The brand has changed hands several times. After being owned by LVMH, it was bought by Johnson & Johnson in 1993, sold to the private-equity firm Gryphon Investors in 2019, and passed to another investor, Bridgepoint, in January 2024. RoC remains an active, multi-region brand, sold across the United States, Europe and Latin America.

According to the company, RoC began in 1957 when Lissarrague, working at a Parisian pharmacy, set out to make skincare that was both gentle and effective and produced what it describes as the first hypoallergenic formula [3]. Lissarrague was a pharmacist specialising in dermo-pharmacology, and the Rogé Cavaillès pharmacy from which the brand took its name was a dermatology-focused establishment. RoC has operated independently of the original Rogé Cavaillès pharmacy brand.

Sources differ on the exact starting date. The brand's own account, together with editorial coverage in Beauty Independent and BeautyMatter, gives 1957. French Wikipedia lists 1950 in its infobox and refers in its text to 1955, the year it says the first fragrance-free hypoallergenic formulas were developed [9]. A separate date, 1945, marks when Lissarrague took over the Rogé Cavaillès pharmacy, before the brand itself existed.

RoC positions itself as an early mover in several areas of skincare. The company says it pioneered a broad-spectrum sunscreen for ageing prevention in 1960 and later developed liposome technology to carry ingredients deeper into the skin. French Wikipedia records the introduction of non-comedogenic creams — formulas designed not to clog pores — in 1987 [9].

The claim the brand returns to most often is retinol. RoC describes itself as the first company to stabilise retinol, a vitamin-A derivative that is otherwise prone to breaking down, and editorial coverage repeats this account [10]. The sources reviewed here do not fix a specific year for that stabilisation, and the company's dermatologist partnerships are dated to its 1957 founding.

RoC has moved through a series of owners. It was once part of the French luxury group LVMH, which sold it to Johnson & Johnson in 1993 [10]. Under Johnson & Johnson the brand was, in Beauty Independent's description, "a profitable, but smaller asset" within a roughly $14 billion consumer business, and by the late 2010s its United States sales were declining by about 3% a year.

In January 2019 the private-equity firm Gryphon Investors acquired RoC from Johnson & Johnson Consumer, establishing it as an independent company [11]. A later BeautyMatter retrospective refers to Gryphon's ownership "since 2020," apparently the first full operating year, while the transaction itself was announced and closed in January 2019. Five years later, in January 2024, Bridgepoint acquired a majority stake through its Bridgepoint Europe VII fund; Reuters reported the deal at about $500 million, though the parties did not disclose official terms [12].

RoC presents itself as clinical, dermatologist-developed skincare rooted in a French pharmacy heritage. Its stated mission is to help people "extend their skin span" by treating what the company identifies as the root causes of visible ageing — genetics, hormones, environment and lifestyle — rather than only the surface signs. The brand summarises the idea with the line that "your skin should reveal how young you feel—not how old you are" [5].

Much of the company's messaging centres on clinical proof and long-standing dermatologist collaboration, marketed as "100% Clinically Proven" and "65+ Years of Derm Partnerships." RoC maintains an advisory board of dermatologists and plastic surgeons and says it has worked with dermatologists on formula development and clinical trials since 1957 [4].

RoC's range is built around anti-ageing skincare, organised into collections such as Retinol Correxion Line Smoothing, Retinol Correxion Deep Wrinkle and Derm Correxion. Individual products include the Line Smoothing Triple Serum, the Deep Wrinkle Rich Cream and the Derm Correxion Firming Serum Stick, which the site markets with the line "1 Sold Every 35 Seconds."

The company names four flagship ingredients: retinol, vitamin C, hyaluronic acid and its own Hexyl-R Complex. It calls its stabilised retinol "America's #1 Retinol," supported by patents, and claims it delivers "7x more wrinkle reduction than standard Retinol" while staying suitable for sensitive skin. The Hexyl-R Complex, according to RoC, was developed over seven years of research and is "clinically proven to be four times more effective than a leading ingredient at visibly improving skin tone" [6]. Beauty Independent reports the brand holds 26 patents relating to retinol and 35 in total since its founding [10].

The company also frames itself around skin-longevity science. It says it established a Longevity Council of dermatologists, scientists and biotechnology figures, and that it collaborates with Brown University on skin-longevity research [5]. RoC states that it does not test on animals and displays PETA's Global Animal Test Policy logo.

RoC's later years have been covered as a turnaround story. In 2024 Beauty Independent profiled it as a "near-forgotten heritage brand" that became a private-equity growth driver, reporting that retail sales roughly tripled from about $100 million to $300 million between 2020 and 2024, alongside 21 consecutive quarters of market-share gains and some 180 awards over the period [10]. The individual awards are not itemised in the sources reviewed.

RoC is an active brand with a current e-commerce presence and ongoing product launches. It reports strong recent growth under private-equity ownership, with revenue up about 70% since 2020, and is distributed through major retailers in the United States, Europe and Latin America[12]. Following the 2024 Bridgepoint acquisition, the company said it was positioned for further growth in the dermatology and skincare sector.